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Abstract
The aim of this review is to evaluate the effects of omega-3 long chain polyunsaturated fatty acids (n-3 LCPUFA) supplementation in preg-
nant and lactating women and infants during postnatal life, on the visual acuity, psychomotor development, mental performance and
growth of infants and children. Eighteen publications (11 sets of randomized control clinical trial [RCTs]) assessed the effects of the n-3
LCPUFA supplementation during pregnancy on neurodevelopment and growth, in the same subjects at different time points; 4 publications
(2 data sets from RCTs) addressed physiological responses to n-3 LCPUFA supplementation during pregnancy & lactation and 5 publicati-
ons (3 data sets from RCTs) exclusively during lactation. Some of these studies showed beneficial effects of docosahexaenoic acid (DHA)
supplementation during pregnancy and/or lactation especially on visual acuity outcomes and some on long-term neurodevelopment; a
few, showed positive effects on growth. There were also 15 RCTs involving term infants who received infant formula supplemented
with DHA, which met our selection criteria. Many of these studies claimed a beneficial effect of such supplementation on visual,
neural, or developmental outcomes and no effects on growth. Although new well designed and conducted studies are being published,
evidence from RCTs does not demonstrate still a clear and consistent benefit of n-3 LCPUFA supplementation during pregnancy and/or
lactation on term infants growth, neurodevelopment and visual acuity. These results should be interpreted with caution due to methodo-
logical limitations of the included studies.
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Introduction
Docosahexaenoic acid (DHA) and arachidonic acid (AA) are
important to foetal and infant growth and development.
Observational and intervention studies provide consistent evi-
dence that maternal dietary and circulating DHA is an import-
ant determinant of foetal blood concentrations of DHA(1–6).
Although linoleic acid (LA) and a-linolenic acid (ALA), and
preformed long chain polyunsaturated fatty acids (LCPUFAs),
can be transported through the placenta, there is a preferential
transfer of the latter forms(6,7). Several studies have assessed
the effect of prenatal LCPUFA dietary supplementation on
pregnancy outcome, aiming to improve it—i.e., preventing
preeclampsia, prolonging gestation, preventing preterm
birth, and improving foetal growth(3,8–9).
On the other hand, the importance of DHA in central ner-
vous system (CNS) development is one of the most intensely
studied areas (10–14). DHA functions in neurogenesis, neuro-
transmission and protection against oxidative stress(15). AA
is also important for infant growth and development. n-3
and n-6 LCPUFA are critical for infant and child brain develop-
ment; they are involved in numerous neuronal processes, ran-
ging from effects on membrane fluidity to gene expression
regulation(16). Brain accumulation of DHA starts in utero,
with quantitatively marked deposition in the second half of
gestation(17–19), coinciding with the growth spurt in the
grey matter(19). Deficiencies and imbalances of LCPUFAs are
associated with impairments in cognitive and behavioural
performance(19–20).
Fish intake during pregnancy and a higher n-3 LCPUFA
status at birth were associated with a better visual develop-
ment in infants born at term(20–22). However, levels of DHA
and eicosapentaenoic acid (EPA) are often low in the Western
diet(23–24). It remains controversial whether LCPUFA sup-
plementation to pregnant and breastfeeding mothers is bene-
ficial for the development of their infants(25–26), optimal doses
for efficacy and long-term effects at different developmental
ages remain to be determined. Today, there are in excess of
40 perinatal randomized controlled trials involving LCPUFA
interventions assessing different aspects of early childhood
development and growth(29).
The earliest publications in human infants from the early
1990s showed that preterm infants fed a formula sup-
plemented with n-3 LCPUFA, mainly as DHA, had improved
retinal sensitivity and visual acuity compared with preterm
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infants fed the standard un-supplemented formulas of the
day, which were low in n-3 PUFA (most were lacking
alpha-linolenic acid) and were rich in n-6 PUFA(28–30). Other
intervention studies has also provide evidence that dietary
DHA improves visual, mental, and motor skill development
in some preterm and term infants fed supplemented
formula(31–34). In a non-randomised observational study,
term infants fed breast milk have been found to have more
mature visual acuities and correlated to higher erythrocyte
DHA levels than those receiving formula(31). Evidence to
suggest that breast-fed infants have a long term IQ advantage
over those who have been fed formula has been evident in
the literature for many years(35–37). Moreover, we realize
that the majority of comparisons between breast fed and
formula-fed infants are confounded by genetic polymorph-
isms that affect LCP metabolism and socioeconomic factors
which affect the outcomes of most studies(38–40).
The present review was undertaken to systematically assess
the evidence of short and long-term effects of n-3 LCPUFA
supplementation during pregnancy and/or postnatal life on
the visual acuity, psychomotor development, mental perform-
ance and growth of children.
Methods
Criteria for considering studies for this review (Table 1)
Types of interventions: inclusion criteria. All relevant RCTs
with LCPUFA intervention in healthy pregnant women,
lactating mothers and healthy full-term infants ($37 weeks
gestation at birth) were elegible for inclusion.From the ran-
domised control trials RCTs or quasi-RCTs found in literature,
only the ones designed to study the effects of n-3 LCPUFA sup-
plementation on any standardized measures of growth, psy-
chomotor development, mental performance and visual
acuity in the offspring were selected. A trial was defined as
quasi-random if the method used to allocate study pregnant
women or infants to the study group was either not statistically
random or was not clearly stated.
Interventions during pregnancy, lactation and with
infant formula for full-term infants with DHA plus AA
or DHA alone were included to be compared to those un-
supplemented or receiving placebo during pregnancy or
postnatally.
LCPUFA supplements could be from any source including
fish oil, egg triglycerides or fungal oils. Trials in which precur-
sor essential FAs (a-linolenic and linoleic acids) were used in
the intervention group were not included, because intake of
the precursors is far less effective with respect to LCPUFA
deposition in fetal brain.
Studies involving prenatal and lactating mothers sup-
plementation were assessed independently from studies with
postnatal supplementation of infant formula.
The selection of interventions with infant formula in full-
term infants had the following criteria: 1) Study formula was
commenced within two weeks after birth; 2) Study formula
was the only source of milk from the time of randomisation
until at least 8 weeks of age; 3) A minimum of three months
follow-up data on clinical outcomes of interest was available.
Types of interventions: exclusion criteria. Trials in women
with high-risk pregnancies were not included, with high-risk
pregnancy being defined as one in which a condition places
the mother, the developing foetus, or both at higher-than-
normal risk for complications during or after pregnancy and
birth (e.g., a preterm delivery during an earlier pregnancy,
intrauterine growth retardation, pregnancy-induced hyperten-
sion, or multiparity).
We excluded studies if the title and abstract were not rel-
evant; however, we obtained articles for all potentially rel-
evant studies if the abstract contained insufficient
information to warrant exclusion. All areas of disagreement
were discussed by the reviewers to achieve a consensus,
and taken also into account the quality assessment.
Trials which used breast milk in addition to study formula
during the first 8 weeks of life were not included to address
the effect of early intervention with LCPUFA in formula-fed
term infants. Trials reporting on only biochemical outcomes
were also excluded.
Types of outcome measures. Visual acuity: measured
either using Teller cards, visual evoked potentials (VEP), elec-
troretinography (ERG), electroencephalography (EEG) and
steroacuity. Neurodevelopmental outcomes: General Quoti-
ent, Intelligent Quotient, Psychomotor Scores, Behavior and
other measures of Cognitive Functions. Growth: weight,
length, head circumference and/or BMI.
Table 1. Inclusion and exclusion criteria established for the systematic
review
Inclusion criteria – RCTs designed to study the effects of n-3
LCPUFA supplementation on growth, visual
acuity and neurodevelopment
– Studies involving supplementation with DHA plus
AA or DHA alone in healthy pregnant women
– Studies involving supplementation with DHA plus
AA or DHA alone in healthy lactating mothers
– Studies involving supplementation with DHA plus
AA or DHA alone of infant formula in healthy full-
term infants ($37 weeks gestation at birth)
– Study formula commenced within two weeks after
birth
– Study formula as only source of milk from the
time of randomisation until at least 8 weeks
of age
– A minimum of three months follow-up data
available on clinical outcomes of interest.
Exclusion criteria – Trials in women with high-risk pregnancies
– Trials in which precursor essential FAs
(a-linolenic and linoleic acids) were used
in the intervention group.
– Title or abstract not relevant
– Trials which used breast milk in addition to study
formula during the first 8 weeks of life
– Trials reporting on only biochemical outcomes
– Certain publication types (Letters to the editor,
abstracts and proceedings from scientific
meetings)
RCTs: Randomized clinical trials; DHA: Docosahexaenoic acid; AA: Arachidonic
Acid; FAs: Fatty acids.
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Search methods for identification of studies
The search strategy included the use of a validated filter for
identifying RCTs(41) which was combined with a topic specific
strategy using the following PubMed’s MeSH terms: (FA OR
omega-6 OR omega-3 OR n-6 OR n-3 OR eicosapentaenoic
acid OR EPA or docosahexaenoic acid OR DHA OR arachido-
nic acid OR AA OR LCPUFA OR long-chain FA OR essential FA
OR fish oil) AND (mother supplementation OR pregnancy OR
lactation OR breastfeeding OR infant formula) AND (Infant
OR Newborn OR Neonate) AND (growth OR weight OR
length OR height OR head circumference) AND (cognitive
function OR development OR neurodevelopment OR psycho-
motor development OR memory OR attention OR language OR
intelligence OR cognition OR visual function OR visual acuity
OR electroretinogram OR visual evoked potentials OR VEP OR
behaviour OR neurobehaviour) AND (Clinical Trial OR Ran-
domised Controlled Trial OR Review). The reference lists of
identified studies and key review articles, including previously
published reviews, as well as, major epidemiological studies
and position papers, were also searched for all studies that
assessed the effects of n-3 LCPUFA supplementation on child
growth, neurodevelopment and/or visual function. We per-
formed a computerized literature search of MEDLINE (from
1966 to April 2011), EMBASE (from 1980 to April 2011),
LILACS (from 1980 to April 2011) and the Cochrane Central
Register of Controlled Trials (CENTRAL, the Cochrane Library
(issue 4, 2011). We imposed no limit with respect to the
language of publication, but certain publication types (i.e.,
letters to the editor, abstracts, and proceedings from scientific
meetings) were excluded.
Quality assessment of trials
The assessment of the quality of the studies that met the
inclusion criteria was made separately by CC and MVE, with
the knowledge of the authors or journals being assessed.
The subsequent strategies associated with good-quality studies
were evaluated: generation of allocation sequences and allo-
cation concealment; blinding of investigators, participants,
outcome assessors, and data analysts (yes, no, or not
reported); intention-to-treat analysis (yes or no); and compre-
hensive follow-up. The generation of allocation sequences
was considered adequate if the resulting sequences were
unpredictable, such as computer-generated random numbers,
and inadequate if the resulting sequences were predictable.
The quality of allocation concealment was considered appro-
priate only if the randomization method applied unable the
investigator or the participant to recognize or influence the
intervention group before enrollment in the study. Allocation
concealment was considered unclear when researchers
claimed to have applied randomization methods but gave
no description about it; it was considered inadequate when
the randomization methods were unsuitable.
In relation to blinding methods, we have analyzed: double-
blind (neither patients, care providers or assessors knew which
treatment was being performed), single-blind (either patients
or care providers or assessors were aware of treatment), and
open (all parties were aware of treatment). For studies with
an intention-to-treat analysis, a positive finding on the
reviewers’ part meant that the authors had specifically
reported undertaking this type of analysis or that our own
study confirmed this finding or both. On the contrary, a nega-
tive finding either meant that authors did not report the use of
intention-to-treat analysis, that we could not confirm its use on
study assessment, or both. We have established the percentage
of participants excluded or lost to follow-up in order to evalu-
ate how complete was patient follow-up. Such was considered
adequate if $80 % of participants were included in the final
analysis; if no losses to follow-up were reported we assumed
that the study completeness was adequate. Furthermore, we
categorized the risk of bias by the number of criteria judged
inadequate in each study: low risk of bias (#1 inadequate
criterion), medium risk of bias (#3 inadequate criteria), and
high risk of bias (.3 inadequate criteria).
Data collection
Two review authors (CC and MVE) assessed eligibility of
studies for inclusion independently. CC and MVE initially
screened the title, abstract, and key words of every report
identified by the search strategy; the reviewers then retrieved
the full text for potentially relevant trials and for reports whose
relevance was not clear. Three of us (CC, MVE and TA) inde-
pendently applied the inclusion criteria to each potentially rel-
evant trial to ascertain its eligibility. If differences in opinion
existed, they were resolved by discussion. Differences in the
inclusion of trials according to their quality were resolved
after consultation with the other review authors (HS and
RU). Data from each study were extracted by all of the
reviewers using standardized data extraction forms prepared
by CC and MVE. After extraction, all data were compared to
minimize the possibility of errors.
Data synthesis (Statistical methods)
The mean difference (MD) between the treatment and control
groups was selected to represent the difference in continuous
outcomes with a 95 % confidence interval (CI). This was
feasible when the mean values of the outcomes, the standard
deviations of the outcomes, and the number of participants in
whom the outcome was assessed in each of the 2 groups were
available. If not, the analyses reported by the authors of the
original articles are presented.
Results
Recently published systematic reviews and meta-analyses
on this topic were identified(25–26,42–47) and subsequently
relevant references of published RCTs were found.
Included studies
All RCTs included in this systematic review were fully peer-
reviewed publications.
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Included RCTs analyzing the effects of LCPUFA
intervention on mothers during pregnancy and/or
lactation (Figure 1)
From a total of 105 existing RCTs designed to analyze the
effect of LCPUFA intervention on mothers during pregnancy
and/or lactation, 16 studies met the selection criteria. The
included trials described 11 study populations for neurodeve-
lopment outcome and 13 study populations assessed the
growth outcome (including a total of 4524 participants), in
infants and children born from supplemented pregnant and/
or fed from their supplemented mothers during lactation.
The general characteristics of these RCTs Table 2.
The time of neurodevelopment and physical growth assess-
ment varied from birth to 7 years. The visual evaluations were
performed during the age range of 0 to 5 years, and they dif-
fered from one another with regard to the vision-testing pro-
tocols and the number of vision testers.
Eighteen publications (including 11 sets of RCTs) assessed
the effects of the n-3 LCPUFA supplementation during preg-
nancy on neurodevelopment and physical growth, on the
same groups of patients and at different time points(48–65), 4
publications (2 sets of RCTs) explored the effect of n-3
LCPUFA supplementation during pregnancy & lactation (66–69)
and 5 publications (3 sets of RCTs) exclusively during
lactation (70–74).
Six publications were focused on analyzing the supplemen-
tation to mothers during pregnancy with n-3 LCPUFA on child
neurodevelopment (48,53–56,64), 5 papers reported results on
visual acuity (48–51,64), and 14 articles examined the effect on
growth as an outcome(48–52,54,57–64).
3 articles, from the same RCT study population, explored
the effect of n-3 LC-PUFA supplementation during pregnancy
& lactation on the offspring neurodevelopment(66–68) and 4
published RCTs explored the effect on infant and children
growth(66–69).
5 publications (3 sets of RCTs) analyzed the effect of supple-
menting lactating mothers on their offspring neurodevelop-
ment(70–74), which was assessed using different tests and
neurophysiologic procedures, as summarized in Table 2.
Included RCTs analyzing the effects of LCPUFA
supplemented infant formulas (Figure 2)
From 21 identified RCTs to analyze the effects of LCPUFA sup-
plemented infant formulas on neurodevelopment and physi-
cal growth, 15 met criteria and thus were selected for inclusion
in this review. The included RCTs described 15 study popu-
lations for neurodevelopment outcome and 13 study popu-
lations assessed the physical growth outcome (including a
total of 2061 infants and children), from birth to 2 years of
age. The general characteristics of these RCTs are shown in
Table 3.
Seventeen publications (7 sets of RCTs) assessed the
effects of the n-3 LCPUFA supplementation of infant formula
on neurodevelopment and physical growth, in the same
groups of patients and at different time points(32–34,75–89).
Another 9 RCTs which reported the complete study in a
single publication were included in this review(90–97).
Thirteen papers reported the effect of n-3 LCPUFA
supplementation of infant formula on visual
acuity(34,75,78,80,83–86,88,90,92,96–97), 17 publications analyzed
the effect on neurodevelopment(32–33,75,77–89,91–92,95,97) and
13 articles reported the effect on physical growth from differ-
ent RCTs(33,76,80–84,86,88,90–94).
LCPUFA supplementation during pregnancy and lactation
Visual acuity (results are summarized in Table 4) . Malcolm
et al. found no significant differences in implicit times, ampli-
tudes or parameters of the stimulus-response function in
the electroretinogram in the first week of postnatal life com-
paring infants born to mothers receiving, from 15 weeks of
Potentially relevant RCTs identified
and screened for retrieval (n :105)
RCTs excluded, citations excluded after
screening title and abstract (n :76)
RCTs retrieved for more detailed
evaluation (n : 29)
RCTs excluded, because non adequate
generation of allocation sequences,
unclear allocation concealment, no
blinding or unclear, participants,
incomplete outcome data addressed, no
intention to treat analysis or non
comprehensive follow-up (n :13)
RCTs with usable information,
by outcome (n :16)
(data from 27 manuscripts)
Fig. 1. Flow chart of the included RCTs analyzing the effects of LCPUFA intervention on mothers during pregnancy and/or lactation.
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Table 2. Characteristics of the included Randomized Clinical Trials (RCTs) related to analyze the effect of supplementation during pregnancy and lactation on growth and neurodevelopment
N8
Author/publication
year
Intervention
Control Period
Growth parameters & Neurological
examination
Growth & Neurodevelopment
outcomes(n-3 LC-PUFA dose/day) Anthropometry/Test Age
Supplementation during pregnancy
1 Smithers et al.
2011(65)/Australia
Three 500-mg/d capsules of
DHA-rich FO concentrate,
providing: DHA: 800 mg/d
EPA: 100 mg/d (n ¼ 89)
Three 500-mg/d vegetable oil
capsules without DHA
(n ¼ 93)
From ,21
weeks of
pregnancy
until delivery
Sweep VEP 4 mo DHA supplementation in
women with singleton preg-
nancies does not enhance
infant visual acuity in infants
at 4 mo of age.
2 *Makrides et al.
2010(64)/Australia
As above (n ¼ 351) As above (n ¼ 375) As above BSID-III 18 mo No differences between
groups
3 Campoy et al.
2011(56)/Spain,
Germany,
Hungary
FO (500 mg/d DHA
þ150 mg/d EPA) (n ¼ 37),
or FO þ 400mg 5-MTHF
(n ¼ 37)
Placebo (n ¼ 45) or 400mg/d
5-MTHF (n ¼ 35)
From 20
weeks of
gestation
until delivery
K-ABC 6 12 y No differences between
groups in K-ABC
Children whose mothers
had higher DHA percen-
tages in erythrocyte PE at
delivery were more likely to
have a MPC score of the
Kaufman ABC over the 50th
percentile at 6·5 y.
4 Escolano-Margarit
et al.
2011(55)/Spain,
Germany,
Hungary
FO (500 mg/d DHA
þ150 mg/d EPA) (n ¼ 43),
or FO þ 400mg 5-MTHF
(n ¼ 37)
Placebo (n ¼ 47) or 400mg/d
5-MTHF (n ¼ 40)
From 20
weeks of
gestation
until delivery
Hempel test
Touwen test
4 y
5 12 y
No differences between
groups
No differences between
groups
Better neurological optimality
scores in children at the age
of 5·5 y with increasing
DHA levels in cord blood at
delivery
5 Courville et al.
2011(59)/USA
DHA cereal-based 5 bars/
week DHA: 300 mg
(EPA:DHA ¼ 1:8) Mean
intake: 214 mg DHA/d
(n:22)
Placebo (n:25) Maize oil
(n:22)
From 20–24
weeks until
delivery
Weight, Length, HC At birth No statistical differences
between supplemented
groups
6 Stein et al.
2011(62)/Mexico
Algal oil capsules DHA:
400 mg/day
(Median DHA intake:
55 mg/d) (n ¼ 370)
Placebo (n ¼ 369) From 18–22
weeks until
delivery
Weight, Length, HC 18 mo Heterogeneity of associations
by maternal gravidity for
weight, length and head cir-
cumference. (n:739; 76 % of
the birth cohort)
Offspring of supplemented pri-
migravide mothers had
higher length than controls.
7 Ramakrishnan et al.
2010(58)/Mexico
Algal oil capsules DHA:
400 mg/day (Median DHA
intake: 55 mg/d) (n: 540)
Placebo (n:554) From 18–22
weeks until
delivery
Weight, Length, HC At birth Offspring of supplemented pri-
migravide mothers were
heavier (n:370) and had lar-
ger head circumferences
than controls (n:603).
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Table 2. Continued
N8
Author/publication
year
Intervention
Control Period
Growth parameters & Neurological
examination
Growth & Neurodevelopment
outcomes(n-3 LC-PUFA dose/day) Anthropometry/Test Age
8 Dunstan et al.
2008(48)/Australia
Fish oil capsules: DHA:
2·2 g/d þ EPA: 1·1 g/d
(n ¼ 52)
Olive oil capsules: n-9 oleic
acid
2·7 g/d (n ¼ 46)
From
20 weeks
gestation
until delivery
Weight and Length
GMDS
PPVT
CBCL
At birth
2 12 y
No differences in growth
between groups
GMDS: supplemented group
(S): higher eye hand coordi-
nation. No differences for
mean general quotient and
other subscales.
S: Significant positive corre-
lation between eye and
hand coordination and n-3
LC-PUFA in cord blood.
S: Inverse correlation
between eye and hand
coordination and performance
score with AA in cord blood.
PPVT: No differences; CBCL:
No differences.
9 Innis & Friesen
2008(51)/Canada
Capsules with DHA from the
Crythecodinium cohnii (DHA
< 0·4 g/d; n ¼ 67)
Soybean and corn oil cap-
sules: LA 0·53 g, ALA
0·08 g/d (n ¼ 68)
From 14–16
weeks ges-
tation until
delivery
Weight and Length
VEPc
Teller acuity Card
At birth
60 ^ 3 days
No differences in growth
between groups
No differences between
groups; Differences
between boys and girls;
Increased risk of low visual
acuity among 60-d-old
infants of mothers following
their usual diet compared
with infants of DHA sup-
plemented women.
10 Judge et al.
2007b(53)/USA
DHA-containing: Cereal-based
bars
(300 mg as low EPA fish oil:
EPA:DHA 1:8); (<DHA
214 mg/wk) (n ¼ 16)
Cereal-based Placebo bars
with Corn oil (n ¼ 14)
From 24
weeks ges-
tation until
delivery
2 step problem solving test
from Willatts Fagan Test of
Infant Intelligence
9 m Problem solving: S Group bet-
ter performance.
Fagan Test of Infant Intelli-
gence: No differences (rec-
ognition memory abilities).
11 Judge et al.
2007a(52)/USA
As above (n ¼ 14) As above (n ¼ 15) As above Growth
Teller acuity cards
At birth
4 m & 6 m
No differences in growth
between groups
Better Visual Acuity at 4 m, no
differences at 6 mo
12 Tofail et al.
2006(54)/Bangla-
desh
Fish oil capsules containing
DHA 1·2 g/d þ EPA 1·8 g/d
(n ¼ 200)
Soy oil capsules:
LA: 2·25 g/d
LNA: 0·27 g/d (n ¼ 200)
From 25
weeks ges-
tation until
delivery
Weight & Length
BSID II
Psychosocial stimulation at
home (HOME)
At birth
10 m
No differences between
groups
13 Sanjurjo et al.
2004(63)/Spain
Fat (2 g/d); 200 mg
DHA/d þ 40 mg EPA/d
Placebo From weeks
27–28 of
gestation to
delivery
Weight At birth No differences between
groups
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Table 2. Continued
N8
Author/publication
year
Intervention
Control Period
Growth parameters & Neurological
examination
Growth & Neurodevelopment
outcomes(n-3 LC-PUFA dose/day) Anthropometry/Test Age
14 Smuts et al.
2003a(60)/USA
High-DHA eggs: DHA:
135 mg/egg; mean intake
¼ 206 ^ 112 mg/DHA/d
(n ¼ 27)
Ordinary eggs (n ¼ 25): DHA:
18 mg/egg; mean intake
¼ 23 ^ 9 mg/d; Low-egg
intake group (n ¼ 26) mean
DHA intake ¼ 7 ^ 9 mg/d
Possibly 3rd
trimester (no
information
provided);
mean: <13
wk
Weight, Length, HC At birth No differences between
groups
15 Smuts et al.
2003b(61)/USA
High-DHA eggs (n ¼ 176):
DHA: 133 mg/egg; mean
intake 7·2 ^ 3·4 eggs/wk
¼ 137 ^ 65 mg/DHA/d
Ordinary eggs (n ¼ 174):
DHA: 33 mg DHA/egg;
intake ¼ 7·3 ^ 3·4 eggs/wk
¼ 34 ^ 16 mg DHA/d
From weeks
24–28 of
gestation to
delivery
Weight, Length, HC At birth DHA intake correlated with
birth weight
16 Malcolm et al.
2003b(49)/UK
Fish oil capsules: 0·1 g of
DHA in 0·323 g oil per cap-
sule DHA 0·2 g/d (EPA:DHA
1:6) (n ¼ 50)
Sunflower oil capsules
0·323 g/d (81 % oleic acid)
(n ¼ 50)
From 15
weeks of
gestation
until delivery
Visual assessment
Transient flash VEP
Pattern-reversal stimuli VEP
1, 50 & 66
weeks
post-con-
ceptional
age
No differences between
groups
Peak latency of the P100 was
4·6 ms shorter for infants
with 1 % higher DHA status
in umbilical cord.
Association between DHA sta-
tus of infants at term and
early postnatal pattern-
reversal VEP
17 Malcolm et al.
2003a(50)/UK
As above As above As above Weight, Length & HC
VEP
Scotopic Electroretinography
At birth
1 week of
life
No differences in growth
between groups
No differences between
groups.
Infants in the highest quartile
for cord blood DHA had
higher retinal sensitivity
compared with infants in the
lowest quartile.
18 Olsen et al.
1992(57)/Denmark
Fish oil (4 g/d): DHA:
920 mg/d þ EPA:
1280 mg/d Vit E: 2 mg/d
<2·7 g n-3 PUFA/d
Olive oil (4 g/d) or no oil
supplement
From week 30
of gestation
until delivery
Weight
Length
at birth No statistical differences
between groups
Supplementation during pregnancy and lactation
1 Helland et al.
2008(68)/Norway
Cod liver oil Containing DHA:
1·183 g/d þ EPA:
0,803 g/d þ vitamins A, D
and E (n ¼ 82)
Corn oil containing LA:
4·747 g/d þ ALA:
0,092 g/d þ vitamins A, D
and E (n ¼ 61)
From 17–19
weeks of
gestation
until 3 m
after delivery
Weight, Height, BMI
K-ABC
7 y No significant differences in
growth
No significant differences in
scores on the K-ABC
between groups.
2 Lucia et al.
2007(69)/Germany
Supplement consisting Fish
oil: DHA 200 mg þVitamins
and minerals þ4·5 g FOS
(n ¼ 43)
(n ¼ 74) Basic supplement
containing: Vitamins & min-
erals or Vitamins & minerals
& 4·5 g FOS
From 21st
week of ges-
tation until 3
mo after
delivery
Weight, Length, HC 1, 3, 21 mo Significant lower BMI and birth
weight in babies from DHA
supplemented mothers, at
1, 3 and 21 mo
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Table 2. Continued
N8
Author/publication
year
Intervention
Control Period
Growth parameters & Neurological
examination
Growth & Neurodevelopment
outcomes(n-3 LC-PUFA dose/day) Anthropometry/Test Age
3 Helland et al.
2003(67)/Norway
As above (n ¼ 48) As above (n ¼ 52) As above K-ABC 4 y Higher Mental Processing
Composite scores of the K-
ABC at 4 y in children from
DHA and EPA sup-
plemented mothers. MPC 4
years correlated with
maternal intake of DHA and
EPA.
4 Helland et al.
2001(66)/Norway
As above (n ¼ 175) As above (n ¼ 166) As above Weight, Length, HC
EEG
Fagan Test of Infant Intel-
ligence
At birth
2 d, 3 mo
6 mo, 9 mo
No differences in growth
between groups
No differences in EEG scores
or Fagan scores.
Neonates with mature EEG
(N ¼ 70) had a higher con-
centration of DHA in umbili-
cal plasma phospholipids
than neonates with imma-
ture EEG (N ¼ 51) on the
second day of life.
Supplementation during lactation
1 Cheatham, et al.
2011(73)/Denmark
Microencapsulated Fish oil
added to mu¨sli bars or to
homemade cookies or as
capsules containing n-3 LC-
PUFA 1·5 g/d (DHA <
0·9 g/d); low content of EPA
(n ¼ 36)
Microencapsulated Olive oil
added to mu¨sli bars or to
homemade cookies or as
capsules (n ¼ 28)
For 4 months
after delivery
Stroop task
Strength and Difficulties
Questionnaire
7 y Negative effect on pro-social
behavior score in boys
Speed of processing scores
were predicted by maternal
n-3 LCPUFA scores (nega-
tive relation) and maternal
education (positive relation)
Stroop scores: working mem-
ory and inhibitory control
were predicted by infant
erythrocyte DHA status at 4
months (negative relation).
2 Jensen et al.
2010(74)/USA
Algal oil capsules
(< 200 mg/d DHA)
(n ¼ 114)
Vegetable oil capsules: LA:
56·3 %, ALA: 3·9 %
(n ¼ 113)
For 4 months
after delivery
Gross and fine motor function;
Perceptual/visual-motor
function; Attention, Execu-
tive Function; Verbal skills;
Sweep VEP, transient VEP
and Bayley-Lovie cards
5 y No differences in visual func-
tion between groups
Children whose mothers
received DHA versus pla-
cebo performed significantly
better on the Sustained
Attention Subscale of the
Leiter International Perform-
ance Scale.
3 Jensen et al.
2005(70)/USA
As above As above Teller Acuity Card
Sweep VEP
BSID
4 and 8 m
12 and 30 m
Lower amplitude in babies
from DHA supplemented
mothers
Higher PDI at 30 mo of age in
children from DHA sup-
plemented mothers.
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Table 2. Continued
N8
Author/publication
year
Intervention
Control Period
Growth parameters & Neurological
examination
Growth & Neurodevelopment
outcomes(n-3 LC-PUFA dose/day) Anthropometry/Test Age
4 Lauritzen et al.
2005(72)/Denmark
Microencapsulated Fish oil
(mu¨sli bars or homemade
cookies or as capsules)
containing n-3 LC-PUFA
1·5 g/d (DHA < 0·9 g/d);
low content of EPA (n ¼ 48)
Microencapsulated
Olive oil added to mu¨sli bars
or to homemade cookies or
as capsules (n ¼ 38)
For 4 months
after delivery
Problem solving ability
Infant linguistic develop-
ment {MacArthur CDI forms
for infant (8–16 mo) & tod-
dler (16–30 mo)}
9 m
1 and 2 y
No significant differences on
problem solving between
groups.
Passive vocabulary was lower
in children aged 1 of the FO
compared to OO group.
Word comprehension at 1 y
was inversely associated
with erythrocyte-DHA at 4
mo.
Small effect of DHA levels in
breast-milk on early
language development.
5 Lauritzen et al.
2004(71)/Denmark
As above (n ¼ 53) As above (n ¼ 44) As above Infant visual acuity (measured
by Sweep VEP)
2 and 4 mo No differences in the Sweep
VEP patterns between
groups.
Higher red blood cell levels of
n-3 LCPUFA was associ-
ated to better visual acuity
at 4 mo of age
FO: Fish Oil; OO:Olive oil; HC: Head circumference; LCPUFAs: Long chain polyunsaturated fatty acids; LA: Linoleic acid; ALA: a-linolenic acid; DHA: Docosahexaenoic acid; EPA: Eicosapentaenoic acid; GMDS: Griffiths Mental
Development Scales; PPVT: Peabody Picture Vocabulary Test; K-ABC: Kaufman ABC; MPC: Mental Processing Composite; CBCL: Child Behavior Checklist; BSID: Bayley Scales of Infant Development; PDI: Psychomotor
Development Index; MDI: Mental Development Index; MacArthur: CDI: Communicative Development Inventory; VEP: Visual evoked potentials; EEG: Electroencephalography. *Included term and preterm infants.
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pregnancy til delivery, 200 mg of DHA/day supplements
during pregnancy and those receiving placebo(49–50). There
were also no differences in the measures of transient flash
VEP waveform at birth and at the ages of 50 and 66 weeks
postconceptional age (PCA); However, positive associations
were found between infants’ DHA status at birth and the sen-
sitivity and maturity of the rod photoreceptors responses at
birth(49), as well as, with the maturity of the pattern-reversal
VEP at the ages of 50 and 66 weeks(50).
Innis et al. found no significant differences in the Teller
acuity cards at the age of 60 days PCA between infants born
from mothers receiving DHA supplements during pregnancy
and those who didn’t. However, infants in the placebo
group were more likely to have a lower visual acuity than
those born to DHA-supplemented mothers(51). Judge et al.(52)
showed significant main effects for visual acuity at 4 months of
age in those infants whose mothers were supplemented
during pregnancy (DHA group), and no differences at
6 months of age; however, in the regression analysis the
authors show better visual acuity in the offspring of the
DHA supplemented group mothers at 4 months. Smithers
et al.(65) reported results from the DOMInO trial showing
that in those infants whose mothers were supplemented
during pregnancy with 800 mg/d of DHA þ100 mg of EPA,
and were fed only breast milk, the VEP acuity at 4 mo of
age was not different compared to the control group. Laurit-
zen et al. reported no significant differences in Sweep VEP
at 2 and 4 mo in babies whose mothers received fish oil sup-
plementation during lactation; however, higher red blood cell
n-3 LCPUFA content were associated with better visual acuity
at 4 mo of age(71).
Studies based on lactating mothers’ supplementation with
n-3 LCPUFA have shown also some controversial results.
Jensen et al. demonstrated that supplementation to mothers
during lactation with 200 mg/d of DHA determines lower
amplitude in the Sweep VEP in their infants at 4 & 8
months(70), but these differences in visual function (Sweep
VEP, transient VEP and Bayley-Lovie cards) were not
confirmed at 5 years(74).
Neurodevelopment. The main results are shown in Table 5.
Four studies assessed neurological outcome in the first 2
years of life after n-3 LCPUFA supplementation in pregnancy,
none reported significant effects on performance in neuro-
logic tests in the supplemented group; two reported no differ-
ences between the supplemented and control group
performance in the Fagan Test of Infant Intelligence (FTII)
at 6 and 9 months of age(53,66) and three reported no differ-
ences in the BSID at 10th and 18th months(54,70,64). Helland
et al.(66) reported no differences in electroencephalogram
(EEG) maturity at 2 days and 3 months after birth between
groups, but observed that higher EPA and DHA levels were
associated with more mature EEG patterns. Judge et al.(53)
reported a positive effect of supplementation on the 2 step
problem solving test at 9th months post birth. Dunstan et al.
reported better eye and hand coordination in the Griffiths
Mental Development Scales (GMDS) in the supplemented
group at 2.5 years, a significant positive association with n-3
LCPUFA and an inverse correlation with AA in cord
blood(48). Based on our evaluation of the data to date, 3 trials
have reported long term effects of supplementation to date.
Helland et al. reported better performance in the K-ABC
mental development test in the supplemented group com-
pared to control at 4 years of age, but this effect was not
observed when IQ was measured at 7 years. The authors
also report a significant positive correlation between IQ at
4 years and DHA levels in infant plasma at 4th weeks of life
as well as an association between maternal DHA levels at
35 week gestation and IQ in the children at 7 years(67–68).
The NUHEAL trial reported no differences in neurological out-
come of children assessed with Hempel (4 years) and Touwen
examinations (5.5 years) between children born to mothers
receiving fish oil supplements and those who didn’t; but, the
authors also demonstrated better neurological scores in chil-
dren at 5.5 yrs with increasing higher DHA levels in cord
Potentially relevant RCTs identified
and screened for retrieval (n : 21)
RCTs excluded, Citations excluded after
screening title and abstract (n : 3)
RCTs retrieved for more detailed
evaluation (n : 18)
RCTs excluded, because non adequate
generation of allocation sequences,
unclear allocation concealment, no
blinding or unclear, participants,
incomplete outcome data addressed,
no intention to treat analysis or non
comprehensive follow-up (n : 3)
RCTs with usable information,
by outcome (n : 15)
(data from 23 manuscripts)
Fig. 2. Flow chart of the included RCTs analyzing the effects of LCPUFA supplemented infant formulas on visual acuity, neurodevelopment and growth.
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Table 3. Characteristics of the included Randomized Clinical Trials (RCTs) related to analyze the effect of infant formula supplementation on growth and neurodevelopment in term infants
N8
Author/publication
year/country Control Period
Growth & Neurological examination
Growth & Neurodevelopment
outcomes
Intervention
(n-3 LC-PUFA dose/day)
Anthropometry and
Neurological Test Age
1 Drover et al.
2011(75)/USA
Infant formula supplemented with
DHA þ AA from single-cell
algal (Crypthecodinium cohnii)
& fungal (Mortirella alpina) oils,
at different dosis: DHA: 0·32 %
(Enfamil LIPILw) (n ¼ 29),
0·64 % (n ¼ 32) or 0·96 %
(n ¼ 28) þ AA: 0·64 % LA:
16·9 %-17·5 % ALA: 1·61 %-
1·68 %
Infant formula with DHA:
0 %w AA: 0 % (Enfamil
with Iron) (n ¼ 28) LA:
16·9 %-17·5 % ALA:
1·61 %-1·68 %
First 12 mo of
life, sole
source of
nutrition until
< 4 mo of
age
BSID II 18 mo No significant differences in MDI,
PDI or BRS between the sup-
plemented groups.
MDI scores of DHA-supplemented
children were higher than those
who did not received DHA sup-
plementation (pooling those sup-
plemented with DHA).
2 Birch EE et al.
2010(76)/USA
Infant formula supplemented with
DHA þ AA from single-cell
algal (Crypthecodinium cohnii)
& fungal (Mortirella alpina) oils,
at different dosis: DHA: 0·32 %
(Enfamil LIPILw) (n ¼ 83),
0·64 % (n ¼ 85) or 0·96 %
(n ¼ 88) þ AA: 0·64 % LA:
16·9 %-17·5 % ALA: 1·61 %-
1·68 %
Infant formula with DHA:
0 %w AA: 0 % (Enfamil
with Iron) (n ¼ 86) LA:
16·9 %-17·5 % ALA:
1·61 % 2 1·68 %
First 12 mo of
life, sole
source of
nutrition until
< 4 mo of
age
Weight, Length,
weight/length and
HC
Sweep VEP Acuity
1·5, 4, 6, 9,
12 mo
No differences in physical growth
between groups
Infants fed control formula had sig-
nificantly poorer visual evoked
potential visual acuity at 12 mo of
age than did infants who received
any of the DHA-supplemented
formulas (0·32 % to 0·64 %)
(P, 0·001).
3 De Jong C, et al.
2010(77)/The Neth-
erlands
Infant formula supplemented
with: DHA: 0·30 % þ AA:
0·45 % (n ¼ 146)
Standard Infant formula
(n ¼ 169)
Breastfed reference group
(n ¼ 160)
From birth to 2
mo of life
Touwen 9 y No significant differences in neuro-
logical function between groups.
Breast-fed children have a
slightly better neurodevelopmen-
tal outcome than formula fed.
4 Birch EE, et al.
2007(78)/USA
Infant formula supplemented
with(microalgal/microfungal
LCP): DHA: 0·36 % þ AA:
0·72 % (n ¼ 17)
Or only with: DHA: 0·36 %
(n ¼ 16)
Standard Infant formula
(n ¼ 19)
Breastfed reference group
(n ¼ 32)
From birth to 2
mo of life
HOTV visual acuity
Amblyopia Treatment
Study (ATS); Elec-
tronic Visual Acuity
(EVA)
Wechsler preschool &
primary scale of
Intelligence; and
WPPSI-R
4 y No differences in visual acuity
between DHA and DHA þ AA-
supplemented groups compared
to breast fed infants. Control
group showed poorer visual
acuity than breast-fed one.
IQ maturation is similar in the sup-
plemented and control groups to
that of breast-fed infants.
5 Bouwstra H et al.
2005(79/Nether-
lands
Infant formula supplemented
with: DHA: 0·30 % þ AA:
0·45 % (n ¼ 146)
Standard Infant formula
(n ¼ 169)
Breastfed reference group
(n ¼ 160)
From birth to 2
mo of life
Hempel
BSID
6,12,18 mo
18 mo
No significant differences in MDI
nor in PDI between groups
6 Birch EE et al.
2005(90)/USA
Infant formula supplemented
with: DHA: 0·36 % þ AA:
0·72 % (n ¼ 51)
Standard Infant formula
(n ¼ 52)
No breastfed reference
group
From birth to 52
weeks of age
Weight, length
Sweep VEP Acuity
Random dot stereoa-
cuity
6,17,26,
39,52 w
No differences in growth par-
ameters between groups
Infants in the LCPUFA group had a
better visual acuity than control
group at 6,17,26 and 52 w
Steroacuity was significantly better
in the LCP-supplemented group
at 17wk, but not at 39 wk.
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Table 3. Continued
N8
Author/publication
year/country Control Period
Growth & Neurological examination
Growth & Neurodevelopment
outcomes
Intervention
(n-3 LC-PUFA dose/day)
Anthropometry and
Neurological Test
Age
7 Ben XM et al.
2004(91/China
Infant formula supplemented
with: DHA þ AA. The LCPUFA
content of the formula was not
clear. (n ¼ 69)
Standard Infant formula
(n ¼ 52)
Breastfed reference group
(n ¼ 26)
From birth to 6
mo of life
Growth
BSID
6 mo
3,6 mo
No significant differences in weight,
length or head circumference
between groups at 6 mo
No significant differences in MDI
nor in PDI between groups
8 Auestad N et al.
2003(80)/USA
Infant formula supplemented
with: DHA: 0·13 % þ AA:
0·45 % (n ¼ 46)
Or only with: DHA: 0·20 %
(n ¼ 43)
Standard Infant formula
(n ¼ 45)
Breastfed reference group
(n ¼ 63)
First 12 mo of
life, sole
source of
nutrition until
< 4 mo of
age
Weight, length and
HC
Sweep VEP Acuity
Teller cards
Stanford Binet IQ
McArthur CDI
Peabody Picture
Vocabulary Test
39 mo No differences in growth between
groups
No significant differences in Sweep
VEP between groups at 12 mo
No statistical differences in visual
acuity using Teller cards at 3y
No differences between groups in
the Stanford Binet IQ at 39 mo
No differences in cognitive and
language assessment at 39 mo
9 Lucas A et al.
2002(81/England
Infant formula supplemented
with: DHA: 0·32 % þ AA:
0·30 % (n ¼ 154)
Standard Infant formula
(n ¼ 155)
Breastfed reference group
(n ¼ 138)
From birth to 6
mo of life
Weight, length and
HC
BSID
Knobloch, Passama-
nick and Sherrads’
tests
6, 9, 18 mo
18 mo
9 mo
No significant differences in weight,
length or head
circumference between groups at
4,6,9,18 mo
No significant differences in MDI
nor in PDI between groups
10 Auestad N et al.
2001(92)/USA
Infant formula supplemented
(egg/TG): DHA: 0·13 % þ AA:
0·45 % (n ¼ 80) or (fish/fungus
oil: DHA: 0·13 % þ AA: 0·45 %
(n ¼ 82)
Standard Infant formula
(n ¼ 77)
Breastfed reference group
(n ¼ 82)
First 12 mo of
life, sole
source of
nutrition until
< 4 mo of
age
Growth
Teller acuity cards
Fagan test of infant
intelligence
BSID
McArthur’s CDI
Parental reporting of
infant temperament
1, 2, 4, 6,
9, 12 mo
2, 4, 6, 12,
14 mo
6,9 mo
6, 12 mo
6,12 mo
9, 14 mo
6, 12 mo
No significant differences in weight,
length or head circumference
between groups at 4, 6 mo
No significant differences in visual
acuity between groups using
Teller cards
No statistical differences between
groups in the Fagan Test
No significant differences in MDI
nor in PDI between groups at 6
mo or 1 y.
11 Hoffman DR et al.
2000(34)/USA
Infant formula supplemented
with(microalgal/microfungal
LCP): DHA: 0·36 % þ AA:
0·72 % (n ¼ 27)
Or only with: DHA: 0·36 %
(n ¼ 26)
Standard Infant formula
(n ¼ 26)
Breastfed reference group
(n ¼ 29)
From birth to 17
weeks of life
Sweep VEP Acuity
ERG
6,17,26,52
weeks
6w, 17w,
1y
Better visual acuity at both 17 and
52 weeks of age.
More mature electroretinographic
responses at 6 weeks of age.
Supplementation leads to better
visual function later in life (52w).
12 Lapillonne A et al.
2000(93/France
Infant formula supplemented
with: DHA: 0·31 % (n ¼ 12)
Standard Infant formula
(n ¼ 12)
No breastfed reference
group
From birth to 4
mo of life
Weight, Length and
HC
2,4 mo No differences in weight, length or
head circumference between
groups
13 Agostoni C et al.
2000(82)/Italy
Infant formula supplemented
with: DHA: 0·30 % þ AA:
0·44 % (n ¼ 29)
Standard Infant formula
(n ¼ 31)
Breastfed reference group
(n ¼ 30)
From birth to 4
mo of life
Bruner-Lezine test 24 mo No differences on Developmental
Quotient (DQ) at 24 mo
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Table 3. Continued
N8
Author/publication
year/country Control Period
Growth & Neurological examination
Growth & Neurodevelopment
outcomes
Intervention
(n-3 LC-PUFA dose/day)
Anthropometry and
Neurological Test
Age
14 Birch EE et al.
2000(83)/USA
Infant formula supplemented with
(microalgal/microfungal LCP):
DHA: 0·36 % þ AA: 0·72 %
(n ¼ 19)
Or only with: DHA: 0·36 %
(n ¼ 17)
Standard Infant formula
(n ¼ 20)
Breastfed reference group
(n ¼ 20)
From within five
days of birth
till 17 weeks
of life
Weight
Sweep VEP Acuity
BSID II
4, 12 mo
18 mo
No differences in growth between
groups
Better VEP acuity at 4 mo was
associated with a better MDI and
PDI score at 18 mo. 7 points
increase of MDI in the DHA sup-
plemented groups.
15 Makrides M et al.
2000(84)/Australia
Infant formula supplemented
with: DHA: 0·34 % þ AA:
0·34 % (n ¼ 28)
Or only with: DHA (0·34 %)
(n ¼ 27)
Standard Infant formula
(n ¼ 28)
Breastfed reference group
(n ¼ 63)
From the 5 days
to 4 mo of life
Weight, length, head
circumference
Steady state VEP
BSID
6,16,34
weeks 1,2
y
1y & 2y
No differences in growth par-
ameters between groups at 4 mo
Better VEP visual acuity in the sup-
plemented group at 4 mo, but no
differences at 7–8 mo
No significant differences in MDI
nor in PDI between groups
16 Morris G et al.
2000(94)/Wales
Infant formula supplemented
with: DHA: 0·20 % þ AA:
0·40 % (n ¼ 54)
Standard Infant formula
(n ¼ 55)
No breastfed reference
group
From birth to 4
mo of life
Growth 6 weeks;
3,6,12
mo
No differences in weight between
groups at 6 mo
17 Lucas A et al.
1999(33)/England
Infant formula supplemented
with: DHA: 0·32 % þ AA:
0·30 % (n ¼ 154)
Standard Infant formula
(n ¼ 155)
Breastfed reference group
(n ¼ 138)
From birth to 6
mo of life
Weight, Length, Head
circumference,
mid-upper arm cir-
cumference, sum
skinfolds
BSID
Knobloch, Passama-
nick and Sherrads’
tests
6,9,18 mo
18 mo
9 mo
No differences in weight, length or
head circumference between
groups at 6 mo
No significant differences in MDI
nor in PDI between groups
No significant differences between
groups in Knobloch, Passamanik
and Sherrards Development
Screening
Inventory
18 Makrides M
et al.1999(85)/Austr-
alia
Infant formula supplemented
with: DHA: 0·34 % þ AA:
0·34 % (n ¼ 28)
Or only with: DHA (0·34 %)
(n ¼ 27)
Standard Infant formula
(n ¼ 28)
Breastfed reference group
(n ¼ 63)
From birth to 4
mo of life
Weight, length, head
circumference
6,16,34
weeks
and 1 y
& 2 y
No differences in growth
parameters
19 Birch EE et al.
1998(86)/USA
Infant formula supplemented
with: DHA: 0·36 % þ AA:
0·72 % (n ¼ 27)
Or only with: DHA: 0·36 %
(n ¼ 26)
Standard Infant formula
(n ¼ 26)
Breastfed reference group
(n ¼ 29)
From within five
days of birth
till 17 weeks
of life
Growth
Sweep VEP Acuity
Forced-choice prefer-
ential looking acuity
(FPL)
6,17,26,52
wk
17,52 wk
No differences in weight, length or
head circumference between
groups at 6 mo
Infants in the LCPUFA group had a
better visual acuity than control
group
20 Scott DT et al.
1998(87)/USA
Infant formula supplemented
with: DHA: 0·13 % þ AA:
0·45 % (n ¼ 46)
Or only with: DHA: 0·20 %
(n ¼ 43)
Standard Infant formula
(n ¼ 45)
Breastfed reference group
(n ¼ 63)
First 12 mo of
life, sole
source of
nutrition until
< 4 mo of
age
BSID
McArthur CDI
Peabody Picture
Vocabulary Test
1y No significant differences in MDI
nor in PDI between groups
DHA group scored lower on the
Vocabulary Comprehension and
Production Scales
Significant negative correlations
between DHA levels and vocabu-
lary outcomes.
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Table 3. Continued
N8
Author/publication
year/country Control Period
Growth & Neurological examination
Growth & Neurodevelopment
outcomes
Intervention
(n-3 LC-PUFA dose/day)
Anthropometry and
Neurological Test
Age
21 Willatts P et al.
1998(95)/Scotland
Infant formula supplemented
with: DHA: 0·15–0·25 % þ AA:
0·30–0·40 % (n ¼ 34)
Standard Infant formula
(n ¼ 38)
No breastfed reference
group
From birth to 4
mo of life
Problem solving tests 10 mo LCPUFA-supplemented infants had
significantly more intentional sol-
utions than infants who received
control formula
22 Auestad N et al.
1997(88)/USA
Infant formula supplemented
with: DHA: 0·13 % þ AA:
0·45 % (n ¼ 46)
Or only with: DHA: 0·20 %
(n ¼ 43)
Standard Infant formula
(n ¼ 45)
Breastfed reference group
(n ¼ 63)
First 12 mo of
life, sole
source of
nutrition until
< 4 mo of
age
Weight, Length, HC
Sweep VEP Acuity
Teller cards
1,2,4,6,9,12
mo
No differences in growth between
the two groups.
No significant differences in visual
acuity between groups using
Sweep VEP acuity or Teller cards
in all ages
23 Agostoni C
et al.1997(32)/Italy
Infant formula supplemented
with: DHA: 0·30 % þ AA:
0·44 % (n ¼ 29)
Standard Infant formula
(n ¼ 31)
Breastfed reference group
(n ¼ 30)
From birth to 4
mo of life
Bruner-Lezine test 4,12,24 mo No differences on Developmental
Quotient (DQ) at 12 mo
24 Carlson SE
et al.1996(96)/USA
Infant formula supplemented
with: DHA: 0·10 % þ AA:
0·43 % (n ¼ 19)
Standard Infant formula
(n ¼ 20)
Breastfed reference group
(n ¼ 19)
From birth to 1
y of life
Visual Acuity
Teller acuity cards
2,4,6,9,12
mo
No significant differences in visual
acuity between groups using
Teller cards
25 Agostoni C
et al.1995(89)/Italy
Infant formula supplemented
with: DHA: 0·30 % þ AA:
0·44 % (n ¼ 29)
Standard Infant formula
(n ¼ 31)
Breastfed reference group
(n ¼ 30)
From birth to 4
mo of life
Bruner-Lezine test 4 mo Higher Developmental Quotient
(DQ) at 4 mo
26 Makrides M et al.
1995(97)/Australia
Infant formula supplemented
with: DHA: 0·35 % þ EPA and
GLA (n ¼ 13)
Standard Infant formula
(n ¼ 19)
Breastfed reference group
(n ¼ 28)
From birth until
30 weeks of
life
VEP Acuity
BSID
16, 30
weeks
1 y
Infants in the LC-PUFA group had
better visual acuity at 4 mo
No significant differences in MDI
nor in PDI between groups
HC: Head Circumference; LCPUFAs: Long chain polyunsaturated fatty acids; LA: Linoleic acid; GLA: g-Linoleic acid; ALA: a-linolenic acid; DHA: Docosahexaenoic acid; EPA: Eicosapentaenoic acid; IQ: Intelligence Coefficient;
GMDS: Griffiths Mental Development Scales; PPVT: Peabody Picture Vocabulary Test; K-ABC: Kaufman ABC; CBCL: Child Behaviour Checklist; BSID: Bayley Scales of Infant Development; PDI: Psychomotor Development
Index; MDI: Mental Development Index: BRS: Behavior rating scales; CDI: Communicative Development Inventory; FO: Fish Oil; OO:Olive oil; TG: triglycerides; VEP: Visual evoked potentials; EEG: Electroencephalography.
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blood(55). Moreover, children whose mothers had higher DHA
content in erythrocyte phosphatidylethanolamine (PE) at
delivery were more likely to have a Mental Processing Compo-
site (MPC) score of the Kaufman ABC over the median at 6·5
yrs. Likewise higher AA/DHA ratio in maternal erythrocyte PE
at delivery was associated with greater proportion of low MPC
scores (below the median)(56).
Lauritzen et al. demonstrated that passive vocabulary at 1 yr
of age was lower in children whose mothers were sup-
plemented with fish oil during lactation, compared to those
babies whose mothers received olive oil; in the same study
the authors reported that word comprehension at 1 yr of
age was inversely associated with erythrocyte-DHA content
at 4 mo additionally a small effect of breast-milk DHA was
noted on early language development(71). Jensen et al. in
2005 report a benefit of DHA supplementation during lacta-
tion at 2·5 years of age, despite no differences in infancy(70).
The supplemented group from this cohort of children was
reported to perform better on a test of sustained attention at
the age of 5 years(74). Recently, Makrides et al.(64) have
shown that mean cognitive composite scores and mean
language composite scores of children in the DHA group of
mothers supplemented during pregnancy did not differ from
children in the control group.
Cheatham et al.(74) reported that early fish oil supplemen-
tation during lactation could have a negative effect on later
cognitive abilities, suggesting a need to target an optimun
DHA level, below and above which, there could be detrimen-
tal consequences to brain development.
Growth. Most studies included in this review showed no
statistical differences after supplementation with DHA during
pregnancy and/or during lactation in birth weight, length,
weight for length or ponderal index at different
ages(54,58–59,61–62,64).
Smuts et al.(61) showed no significant differences between
groups, but demonstrated that DHA intake correlates with
birth weight. Tofail et al.(54) investigated the effect of fish oil
(1·2 g DHA and 1·8 g eicosapentaenoic acid, EPA 20:5 n-3,
per day) from 25 weeks gestation until birth on growth and
development in 249 mother-infant pairs from a very poor
area of Bangladesh. Birth weight, length, head circumference
and ponderal index did not differ between groups at birth or
at 10 months. Ramakrishnan et al.(58) and Stein et al.(62) stu-
died the effect of DHA supplementation (400 mg/day) com-
pared with placebo in 1094 pregnant women from
Cuernavaca (Mexico), with a low background dietary intake
of DHA (<55 mg/day). Mean gestational age at birth, birth
weight, length and head circumference did not differ between
groups. However, the babies from primiparous women who
received DHA were heavier (þ99 g) and had larger head
circumferences (þ0·5 cm) at birth compared to controls.
These differences were not shown in multigravida
women(58). Makrides et al.(64) in a randomised clinical trial
on 2399 women, supplemented or not with 800 mg/day of
DHA þ 100 mg/day of EPA, showed no significant differences
between groups. Group differences in birth size were largely
explained by gestational age at birth. Finally, Lucia et al.(69)
showed significant lower BMI and birth weight in babies
from DHA supplemented mothers, at 1, 3 and 21 mo.
Table 4. Significant effects found of n-3 LCPUFA supplementation
during Pregnancy or Lactation Child Visual Development
Outcome N Mean difference [95 % CI]
Supplementation during pregnancy
Judge et al. 2007 (52)
Visual acuity scores at 4 months 30 0·5 [20·4, 1·4]*
Malcolm et al. 2003 (50)
Mean peak latency of transient
flash VEP
N3 at 50 weeks PCA 34 235·5 [269·4, 21·6]*
Mothers’ supplementation during
lactation
Jensen et al. 2005 (70)
Teller acuity card at 4 months 147 0·30 (0·09, 0·51)*
Teller acuity card at 8 months 147 21·2 (21·38, 21·02)*
CI ¼ confidence interval, PCA ¼ post-conceptional age. VEP ¼ visual evoked
potential, cpd ¼ cycles per degree, ms: miliseconds, mV ¼ microvoltium, * ¼
significant difference (P,0·05).
Table 5. Significant Effects found of n-3 LCPUFA Supplementation during Pregnancy and
Lactation on Child Neurodevelopment
Outcome N Mean difference [95 % CI]
n-3 LCPUFA Supplementation during pregnancy
Judge et al. 2007 (53)
The 2-step problem-solving test at 9 months
Intention score: cloth average 29 0·6 [20·1, 1·4]
Intention score: cover average 29 0·7 [20·6, 2·0]
Intention score: total average 29 1·3 [20·6, 3·2]*
Intentional solutions: cloth 29 1·1 [0·01, 2·2]
Intentional solutions: cover 29 0·8 [20·3, 1·9]*
Intentional solutions: total 29 0·8 [20·2, 1·8]*
n-3 LCPUFA Supplementation during Pregnancy
& Lactation
Helland et al. 2003 (67)
K-ABC mental processing composite at 4 year 84 4·1 [20·2, 8·4]*
n-3 LCPUFA Supplementation during Lactation
Lauritzen et al. 2005 (72)
MacArthur CDI vocabulary comprehension at 1 year 89 217·0 [234·6, 0·6]*
CI ¼ confidence interval. K-ABC ¼ Kaufman Assessment Battery for Children, *: significant difference
(P,0·05).
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Effects of LCPUFAs supplementation in term infants
Visual acuity. The main results are shown in Table 6.
Some of the included studies exploring the effect of receiv-
ing DHA supplementation in early life on visual acuity, using
different methodologies (Sweep VEP, Steady state VEP, Teller
Acuity Cards, HOTV cards) have reported either no significant
effects or minor effects compared to control groups or breast
fed infants at different stages of infant develop-
ment(80,84–85,88,92). Makrides et al.(97) in a randomized control
trial to assess the effect of infant formula supplemented with
0·35 % of DHA, given from birth to 30 weeks of postnatal
life, reported better visual acuity at 4 mo in the supplemented
infants compared to control group.
Birch et al.(34,83,86) have consistently demonstrated that DHA
(0·36 %) supplementation with or without AA (0·72 %) during
the first 17 weeks of life improved visual acuity at 17, 26
and 52 weeks, and steroacuity(80) at 52 weeks of postnatal
age measured using visual evoked responses and more
mature electroretinographic responses at 6 weeks of age(34).
At 4 years, the supplemented group had a small but statisti-
cally significant effect on visual acuity using HOTV cards for
the right eye (P , 0·03); while the control formula diet
group had poorer visual acuity in the right eye compared to
the breast-fed group (P , 0·004) as well as lower right eye
acuity compared to the DHA containing formula group
(P , 0·03); the DHA- and DHA þ AA-supplemented groups
did not differ significantly from the breast-fed group(78).
Birch et al.(76) recently have published the results of a new
large sample size study from 244 healthy, term, formula-fed,
singleton-birth infants (37–42 wk gestation; 2490–4200 g
birth weight) randomized into four groups (DIAMOND
study): 56/85 (66 %) in the control group, 64/83 (77 %) in
the 0·32 % DHA group, 59/84 (70 %) in the 0·64 % DHA
group, and 65/87 (75 %) in the 0·96 % DHA group. All DHA
supplemented formulas contained 0·64 % arachidonic acid
(AA). Infants were fed the assigned formulas until 12
months of age, and 141 children completed the 12-month
feeding trial(75). Infants fed control formula had significantly
poorer VEP visual acuity at 12 mo of age than did infants
fed any of the DHA-supplemented formulas (P, 0·001).
Neurodevelopment. The main results are shown in Table 7.
Most studies(32,76,80,84,88,92,96–97) included in this review
were randomised controlled clinical trials reporting on the
effect of DHA supplemented infant formula on neurodevelop-
ment using different tests (BSID, Brunetz-Lezine, MacArthur
Comunicative Development Inventory, Stanford Binet IQ,
Hempel, Touwen, Knobloch, Passamanick and Sherrads’
tests) at different ages; no significant differences were found
at 6 mo to 9 yrs of age. Willats et al.(95) demonstrated that
babies fed LCPUFA-supplemented infant formula had signifi-
cantly more intentional solutions than infants who received
control formula at 10 mo. Agostoni et al.(32,82,89) evaluated
the effect of infant formula supplemented with 0·3 % DHA
plus 0·44 % AA compared to a standard formula, using
Brunet-Lezine test, demonstrating higher Developmental Quo-
tient at 4 mo, but not at 1y and 2y in the supplemented infants.
Birch et al.(88) demonstrated 7 points increase of MDI in the
DHA supplemented groups and no significant differences in
PDI and Behavior Rating Scales scores at 18 mo compared
to control group. They also reported that better VEP acuity
at 4 mo was associated to a better MDI and PDI scores at
18 mo. Drover et al.(75) confirmed the previous results asses-
sing cognitive function in a new study including 131 children
at 18 mo of age using the more up to date BSID II reporting
that MDI scores of DHA-supplemented children were higher
than those who did not received DHA supplementation at
18 mo of age; moreover, DHA concentration of 0·32 % was
adequate to improve cognitive function and higher concen-
trations did not confer additional benefit.
Growth. Some of the randomized clinical trial included in
this review, using DHA plus or not in combination with
AA(33,76,78,80–81,83–84,86,88,90–94) reported this outcome. No
studies found statistically significant differences between
LCPUFA and control groups, even if the studies included a
breast fed reference group.
Discussion
The aim of this systematic review of RCTs was to assess whether
n-3 LCPUFA supplementation to pregnant and/or lactating
Table 6. Significant Effects related to n-3 LCPUFA supplementation of
infant formula on infant and child visual acuity
Outcome N Mean Difference [95% CI]
Infant formula supplementation
Birch et al. 2010 (76)
Sweep VEP Acuity 1·5, 4, 6, 9, 12
months
256 Data not available
Birch et al. 2007 (78)
DHA þ AA supplemented vs normal
term infant formula
HOTV acuity (logMAR) RE at
4 years
36 0·042 [0·00075, 20·00072]*
DHA supplemented vs term infant
formula
HOTV acuity (logMAR) RE at
4 years
35 0·053 [0·014, 20·013]*
Birch et al. 2005 (90)
DHA þ AA supplemented vs normal
term infant formula
Sweep VEP Acuity at 4
months
92 20·07 [20·11, 20·03]*
Hoffman et al. 2000 (34)
DHA þ AA supplemented vs normal
term infant formula
Sweep VEP Acuity (logMAR) at
4 months
42 20·06 [20·13, 0·01]*
Sweep VEP Acuity (logMAR) at
12 months
38 20·13 [20·20, 20·06]*
DHA supplemented vs term infant
formula
Sweep VEP Acuity (logMAR) at
4 months
41 20·08 [20·15, 20·01]*
Sweep VEP Acuity (logMAR) at
12 months
40 20·14 [20·21, 20·07]*
Makrides et al. 1995 (97)
Steady state VEP Acuity (logMAR)
at 4 months
26 20·20 [20·32, 20·08]*
PCA ¼ Postconceptional age, VEP ¼ Visual Evoked Potentials, MAR: minimum
angle of resolution, HOTV: Amblyopia Treatment Study (ATS) protocol and the
Electronic Visual Acuity (EVA) system, CI: Confidence Interval, * ¼ significant
difference (P,0·05).
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mothers, and to infant formula, could benefit term infants in
their psychomotor, mental, visual acuity development and
their physical growth. Evidence from the data obtained in the
present review do not demonstrate that n-3 LCPUFA sup-
plementation during prenatal or early life exert a clear and con-
sistent short or long-term benefit of the offspring. Some recent
large sample size studies included in this review reported favor-
able effects of n-3 LCPUFA supplementation on one specific
domain of child development, or on visual acuity development
using electrophysiological assessment. The effect on different
measures of physical growth is null or minor in virtually all
studies. Transient early differences tend to disappear in sub-
sequent assessments. However, there is great heterogeneity
among studies regarding the timing, type, concentration and
duration of LCPUFA supplementation and of the outcomes
assessed and methods used to assess the outcomes. Thus results
of most studies are not comparable. For example, visual acuity
development was measured at 4, 6, 12 months, 3 and 4 years,
using sweep VEP, steady state VEP or teller cards. The neuro-
developmental outcomes were assessed at 3, 4, 6,1 2 months
and at 2, 3, 4, 7 and 9 years in different studies, using different
age-adapted tests. The only exception was physical growth was
assessed at 4, 6, 12 months and 2, 3, 4 years in different studies,
using standard physical measurements or z scores of such
measurements.
SomeRCTs during pregnancy suggest that prenatal DHA
status might have subtle positive effects on neurodevelopmen-
tal and behaviour outcome(70–74), but whether these effects
are maintained beyond early infancy remains a matter of dis-
cussion(97–100). Trials specifically addressing n-3 LCPUFA sup-
plementation during pregnancy and/or lactation consistently
show a direct dose-response relationship between DHA
intake and mothers’ DHA concentration in plasma or erythro-
cyte phospholipids or in human milk, respectively, but have
not consistently demonstrated benefits on developmental out-
comes in children(48–56,64–65,67–68). It is important to note that
some of these RCTs have agreed with the observational and
epidemiological results(46), indicating that a better AA/DHA
status during pregnancy and lactation is related to a better
neurodevelopment outcome in children born at term.
Postnatal supplementation to improve neurodevelopment,
has shown conflicting results in term infants. The follow up
results in young children suggest that neurodevelopment
and cognitive abilities are also enhanced by early provision
of n-3 LCPUFAs through breast milk or DHA-fortified foods.
Breast fed infants also require n-3 LCPUFAs after weaning to
achieve optimal visual acuity at 12 months of age(32,36,101).
Jensen et al.(70,74) reported significant differences in psycho-
motor development and sustained attention at long term
(30 mo and 5 years), favouring the breastfeeding mothers sup-
plemented with DHA.
Makrides et al.(64,84,97) and Birch et al.(34,76,78,86,90) have con-
ducted the largest studies and have shown, in different studies
with multiple repeated measures, that n-3 LCPUFA sup-
plementation to infant formula benefits visual acuity and
mental development indices for up to 4 years. In addition, it
has been reported benefits of LCPUFA supplementation on
MDI scores at 18 months(74,83) and better problem solving
skills at 10 months of age(95). However, these beneficial effects
on vision and neurodevelopment have not been replicated in
other good quality studies(32–33,77,79,81–82,85,88,92,94). In 2003, a
meta-regression analysis of seven trials in term infants showed
that the DHA dose in milk formula was positively related to
visual acuity measurements at age 4 months(36). In 2010,
Beyerlein et al.(44) analysed the results of 4 large randomised
clinical trials in a meta-analysis and they could not find a clini-
cally meaningful effect on the neurodevelopment and visual
acuity in children that received LCPUFA supplemented for-
mula. This served to further raise the discussion on whether
it was valid to continue supplementing DHA to breastfeeding
mothers(72–73) and to term infants fed infant formula(87). Fur-
thermore these investigators reported potential adverse
effects, suggesting that there is an optimum DHA level
below and above which DHA might be detrimental to the
developing brain. We conclude that based on present evi-
dence there is still no clear evidence of long-term beneficial
or harmful effect of LCPUFA supplementation on neurodeve-
lopment or visual function in term infants.
In summary the results shown in this systematic review
demonstrate evidence that n-3 LCPUFA supplementation to
pregnant women determines a modest increases of birth size
in their neonates born at term, especially in primigravi-
das(58,62), independently of low- or high-income populations;
Previous meta-analysis reached similar conclusions, basically a
small but significant increase in the length of gestation (<2·5
days)(25,42–43,47) and a modest increase in infant birth weight
(þ50 g), birth length (þ0·48 cm) and head circumference
(þ0·69 cm) in the offspring’s of women taking DHA sup-
plements(25). The new data emerged from recent randomised
clinical trials have not changed these conclusions, suggesting
that the observed increases in birth weight and birth
length could be the result of the increased duration of
gestation(27,42–43).
Despite numerous randomized controlled trials, meta-anal-
ysis and meta-regression analysis, data after the addition of a
specific amount of LCPUFAs to term infant remain probable
but not convincing for a robust effect(45). Post-natal sup-
plementation with LCPUFA does not appear to influence
Table 7. Significant Effects related to n-3 LCPUFA supplemen-
tation of infant formula on infant and child neurodevelopment.
Data from the Bayley Scales for Infant Development (BSID)
Outcome N Mean difference [95 % CI]
Drover et al. 2011 (75)
DHA þ AA (0·32%)
supplemented vs normal
term infant formula
MDI score at 18 months 57 26·80 [7·38, 4·02]*
Birch et al. 2000 (83)
DHA þ AA supplemented
vs normal term infant
formula
MDI score at 18 months 39 7·30 [0·78, 13·82]*
PDI score at 18 months 39 3·10 [0·15, 6·05]*
Bayley Scales of Infant Development: MDI ¼ Mental Developmental
Index, PDI ¼ Psychomotor Developmental Index, BRS ¼ Behaviour
Rating Scales, CI ¼ Confidence Interval, * ¼ significant difference
(P,0·05).
Omega 3 fatty acids on child growth and development S101
B
ri
ti
sh
Jo
u
rn
al
o
f
N
u
tr
it
io
n
infant growth(27,44). The present systematic review concludes
there is no effect of prenatal or postnatal n-3 LCPUFA sup-
plementation on physical growth.
Considerations about other new important confounders
Common polymorphisms of the genes FADS2 (FADS2, encod-
ing D-6 desaturase) and FADS1 (FADS1, encoding D-5 desatur-
ase) found in about one quarter of the European population,
encoding for the key enzymes regulating endogenous LCPUFA
synthesis, i.e. delta-6-desaturase and delta-5 desaturase, are
associated with markedly reduced plasma LCPUFA concen-
trations(102). First results suggest marked effects of genetic vari-
ation in the FADS gene cluster on relevant clinical end points,
including cognitive development, with potentially major
importance for public health(103). Koletzko et al.(104) showed
a consistent significant association of rare SNP alleles with
lower amounts of DHA in red blood cell phospholipids of
pregnant women; a modulation of DHA status during
pregnancy by frequently occurring FADS genotypes may be
of major relevance for child outcomes. These data are results
from the NUTRIMENTHE EU Project (Grant Agreement:
212652). Further results will clarify the real power of this gen-
etic effect, present in the 30% of the population, on the cogni-
tive outcome during development. It is tempting to speculate
that genetic heterogeneity in fatty acid metabolism may be
one of the reasons, besides differing study design and variable
quality, for the apparent inconsistent results of different
studies that investigated effects of a perinatal supply of DHA
sources on developmental outcome.
Considerations about methodological procedures
Concerns pertaining to the impact of nutrition on neurodeve-
lopment and cognitive performance have emerged over the
past decade, in most cases the focus has been on methodo-
logical considerations and limitations of these studies(105–107).
The sensitivity of the neuropsychological tests to subtle effects
of nutrition(106–107) have been addressed and the need to con-
sider the timing of effects relative to the critical periods
involved in brain developmental process have been
raised(107). In addition, it is now well recognized that neurop-
sychological tests should assess the specific neuropsychologi-
cal domains ( perceptual, motor, attention, learning and
memory, and executive functions) instead of global cognitive
performance; first, to avoid hiding or masking specific effects
of the nutritional intervention and secondly to address the
need to consider the specific biological mechanisms involved.
Cultural local factors need to be considered when comparing
similar neuropsychological tests administered in different
countries, as well as the practice/learning effect(106), especially
if the intention is to test subtle improvements after a nutri-
tional intervention.
A number of novel approaches are now available for the
assessment of nutrition-related variations in brain structure
and function. RCTs with modest sample sizes (N,100) should
consider a combination of structural MRI and functional
MRI with EEG; these would provide the most-comprehensive
assessment of brain structure and function and, hence, offer
insights into possible neural mechanisms underlying the
effect of nutrients on cognition and mental well-being(108).
These new techniques in combination with the neuropsycholo-
gical assessment offer new opportunities to unravel the
interaction between nutrition and brain development in the
near future.
Implications for future research
The complexity of brain development process requires special
attention. The absence of positive results obtained so far
should be analyzed carefully; the existing neuropsychological
tests used up to now are likely not sufficiently sensitive to con-
clude there is “no effect”. Novel more function specific
approaches that combine the assessment of different neuro-
psychological domains should be developed considering the
potential biological mechanism involved for the specific nutri-
ent-effect to be explored. Furthermore, the combination of
new imaging techniques and electrophysiological responses
must be promoted as gold-standard methodologies to detect
objective nutrient effects on brain development.
Regarding the recent emerging results from different
studies, it seems that there is really an optimum DHA level
below and above which there may be detrimental conse-
quences to the developing brain; this should be explored in
low income populations where risk of abnormal brain devel-
opment is greatest considering the need for large sample sizes
and the evaluation of a dose response.
Analyses of FADS gene variants should be mandatory in all
sizeable cohort and intervention studies in order to address
the diet and endogenous individual metabolism interactions
in defining the potential biological effects of LCPUFA; this
should enhance study sensitivity and precision.
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